Although business headlines still tout earnings numbers, many investors have moved past net earnings as a measure of a company's economic output. That's because earnings are very often less ...

It takes money to make money. Most investors know that, but with business media so focused on the "how much," very few investors bother to ask, "How fast?" Let's break this downIn this series, we ...

We have reiterated our Neutral recommendation on Cyberonics Inc. (CYBX) with a target price of $46.00, following our assessment of its fourth quarter and fiscal 2012 results. Cyberonics reported ...

Cyberonics said Wednesday that the expenses associated with an inquiry by the Securities and Exchange Commission, a subpoena from the U.S. Attorney in Manhattan and the company's own review of stock ...

Cyberonics has made a minority investment in Cerbomed GmbH. The inital investment is €2 million (US$2.6 million) but that can total € 5.5 million, subject to the achievement of certain clinical ...

Cyberonics officials on Thursday said the Houston-based company could begin offering a more sophisticated version of its nerve-stimulating device to treat U.S. epilepsy patients as early as next year, ...

Look here for a clue. There's no foolproof way to know the future for Cyberonics (Nasdaq: CYBX) or any other company. However, certain clues may help you see potential stumbles before they happen -- ...

Cyberonics, which makes a device that treats epilepsy, disclosed Monday it received a warning letter last month from the FDA citing problems inspectors found at its Houston manufacturing plant. The ...

On Sep 15, 2015, we issued an updated research report on Cyberonics Inc. CYBX – a Texas-based medical technology company with core expertise in neuromodulation. While it eagerly awaits the completion ...

Cyberonics Inc., maker of a device to treat epilepsy and depression, said Monday that two top executives had resigned after an investigation revealed errors in its accounting practices. Chief ...

So much for efficient markets. Even though Cyberonics' (NASDAQ:CYBX) management had been telling investors for some time that an eventual launch of a therapy for treatment-resistant depression would ...